HC Wainwright Has Optimistic Outlook of Kamada Q1 Earnings

Kamada Ltd. (NASDAQ:KMDA) – Equities research analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Kamada in a report issued on Thursday, March 12th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of $0.14 for the quarter, up from their prior forecast of $0.10. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada’s Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.17 EPS, Q4 2026 earnings at $0.16 EPS and FY2030 earnings at $0.88 EPS.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Wednesday, March 11th. The biotechnology company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). The firm had revenue of $44.68 million during the quarter, compared to analysts’ expectations of $145.07 million. Kamada had a return on equity of 7.72% and a net margin of 11.19%.

Other research analysts have also issued reports about the stock. Stifel Nicolaus set a $11.00 price target on shares of Kamada in a research note on Wednesday, March 11th. Benchmark reissued a “buy” rating on shares of Kamada in a research note on Thursday. Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a report on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Kamada from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Kamada has an average rating of “Moderate Buy” and an average price target of $13.00.

Kamada Trading Up 2.3%

Shares of Kamada stock opened at $8.90 on Monday. Kamada has a 12 month low of $5.54 and a 12 month high of $9.35. The firm has a market capitalization of $511.79 million, a P/E ratio of 25.43, a P/E/G ratio of 0.76 and a beta of 0.94. The business has a fifty day simple moving average of $8.47 and a two-hundred day simple moving average of $7.48.

Kamada Announces Dividend

The company also recently declared an annual dividend, which will be paid on Monday, April 6th. Shareholders of record on Monday, March 23rd will be paid a dividend of $0.25 per share. This represents a dividend yield of 292.0%. The ex-dividend date is Monday, March 23rd. Kamada’s payout ratio is currently 71.43%.

Hedge Funds Weigh In On Kamada

Institutional investors have recently made changes to their positions in the business. Barclays PLC boosted its holdings in shares of Kamada by 417.1% in the fourth quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock worth $34,000 after buying an additional 3,862 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Kamada during the fourth quarter valued at approximately $66,000. Simplicity Wealth LLC purchased a new stake in Kamada during the third quarter valued at approximately $70,000. XTX Topco Ltd bought a new position in Kamada in the fourth quarter worth approximately $103,000. Finally, SIH Partners LLLP purchased a new position in shares of Kamada during the 4th quarter worth $134,000. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.